BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 28895127)

  • 21. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
    Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.
    Pabst T; Eyholzer M; Haefliger S; Schardt J; Mueller BU
    J Clin Oncol; 2008 Nov; 26(31):5088-93. PubMed ID: 18768433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular evaluation of CEBPA gene mutation in normal karyotype acute myeloid leukemia: a comparison of two methods and report of novel CEBPA mutations from Indian acute myeloid leukemia patients.
    Ahmad F; Rajput S; Mandava S; Das BR
    Genet Test Mol Biomarkers; 2012 Jul; 16(7):707-15. PubMed ID: 22731647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML.
    Simon L; Spinella JF; Yao CY; Lavallée VP; Boivin I; Boucher G; Audemard E; Bordeleau ME; Lemieux S; Hébert J; Sauvageau G
    Blood; 2020 May; 135(21):1882-1886. PubMed ID: 32315381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA let-7a-3 gene methylation is associated with karyotyping, CEBPA promoter methylation, and survival in acute myeloid leukemia.
    Ko YC; Fang WH; Lin TC; Hou HA; Chen CY; Tien HF; Lin LI
    Leuk Res; 2014 May; 38(5):625-31. PubMed ID: 24703161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complexity of CEBPA dysregulation in human acute myeloid leukemia.
    Pabst T; Mueller BU
    Clin Cancer Res; 2009 Sep; 15(17):5303-7. PubMed ID: 19706798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.
    Fröhling S; Schlenk RF; Stolze I; Bihlmayr J; Benner A; Kreitmeier S; Tobis K; Döhner H; Döhner K
    J Clin Oncol; 2004 Feb; 22(4):624-33. PubMed ID: 14726504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML).
    Carnicer MJ; Lasa A; Buschbeck M; Serrano E; Carricondo M; Brunet S; Aventin A; Sierra J; Di Croce L; Nomdedeu JF
    Ann Hematol; 2008 Oct; 87(10):819-27. PubMed ID: 18587575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of promoter DNA methylation and expression levels of genes encoding CCAAT/enhancer binding proteins in AML patients.
    Musialik E; Bujko M; Kober P; Grygorowicz MA; Libura M; Przestrzelska M; Juszczyński P; Borg K; Florek I; Jakóbczyk M; Baranowska A; Siedlecki JA
    Leuk Res; 2014 Jul; 38(7):850-6. PubMed ID: 24878001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Analysis of CEBPA mutation in acute myeloid leukemia].
    Zhang Y; Zhang SJ; Qiu HX; Qiao C; Sun HM; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):859-62. PubMed ID: 20723288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma.
    Fuchs O; Provaznikova D; Kocova M; Kostecka A; Cvekova P; Neuwirtova R; Kobylka P; Cermak J; Brezinova J; Schwarz J; Markova J; Salaj P; Klamova H; Maaloufova J; Lemez P; Novakova L; Benesova K
    Blood Cells Mol Dis; 2008; 40(3):401-5. PubMed ID: 18182175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PU.1 and CEBPA expression in acute myeloid leukemia.
    D'Alò F; Di Ruscio A; Guidi F; Fabiani E; Greco M; Rumi C; Hohaus S; Voso MT; Leone G
    Leuk Res; 2008 Sep; 32(9):1448-53. PubMed ID: 18308386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CCAAT/enhancer binding protein-alpha polymorphisms occur more frequently than mutations in acute myeloid leukemia and exist across all cytogenetic risk groups and leukemia subtypes.
    Leecharendkeat A; Tocharoentanaphol C; Auewarakul CU
    Int J Cancer; 2008 Nov; 123(10):2321-6. PubMed ID: 18729193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [THE CLINICAL SIGNIFICANCE OF GENETIC MUTATIONS IN ACUTE MYELOID LEUKEMIA].
    Goryainova NV
    Lik Sprava; 2014 Dec; (12):10-8. PubMed ID: 26638462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLs.
    Gerritsen M; Yi G; Tijchon E; Kuster J; Schuringa JJ; Martens JHA; Vellenga E
    Blood Adv; 2019 Feb; 3(3):320-332. PubMed ID: 30709863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of the unfolded protein response in human acute myeloid leukemia.
    Schardt JA; Mueller BU; Pabst T
    Methods Enzymol; 2011; 489():227-43. PubMed ID: 21266233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reclassification of Acute Myeloid Leukemia According to the 2016 WHO Classification.
    Jung J; Cho BS; Kim HJ; Han E; Jang W; Han K; Lee JW; Chung NG; Cho B; Kim M; Kim Y
    Ann Lab Med; 2019 May; 39(3):311-316. PubMed ID: 30623623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.
    Tang JL; Hou HA; Chen CY; Liu CY; Chou WC; Tseng MH; Huang CF; Lee FY; Liu MC; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Lin LI; Tien HF
    Blood; 2009 Dec; 114(26):5352-61. PubMed ID: 19808697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CEBPA copy number variations in normal karyotype acute myeloid leukemia: Possible role of breakpoint-associated microhomology and chromatin status in CEBPA mutagenesis.
    Libura M; Pawełczyk M; Florek I; Matiakowska K; Jaźwiec B; Borg K; Solarska I; Zawada M; Czekalska S; Libura J; Salamanczuk Z; Jakóbczyk M; Mucha B; Duszeńko E; Soszyńska K; Karabin K; Piątkowska-Jakubas B; Całbecka M; Gajkowska-Kulig J; Gadomska G; Kiełbiński M; Ejduk A; Kata D; Grosicki S; Kyrcz-Krzemień S; Warzocha K; Kuliczkowski K; Skotnicki A; Jęrzejczak WW; Haus O
    Blood Cells Mol Dis; 2015 Dec; 55(4):284-92. PubMed ID: 26460249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia.
    Kiehlmeier S; Rafiee MR; Bakr A; Mika J; Kruse S; Müller J; Schweiggert S; Herrmann C; Sigismondo G; Schmezer P; Krijgsveld J; Gröschel S
    Leukemia; 2021 Nov; 35(11):3127-3138. PubMed ID: 33911178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.